Thus, patients taking the agents associated with the greatest weight loss, tirzepatide and semaglutide, have the highest incidence of developing both hypocalcemia and hypercalcemia
Even at lower doses, semaglutide 1.0 mg achieved a 42% CRP reduction in STEP 2
If not, we want to see how we can moderate our protocols so that the patient undergoing a total hip arthroplasty who is also taking a GLP-1 agonist can have the most ideal experience possible for their surgery.
Incretin hormones cause the body to produce insulin when eating sugar, called the incretin effect
When GLP-1 medications are combined with other diabetes treatments, such as insulin or sulfonylureas, dose adjustments may be needed to lower the risk of hypoglycemia
A 20mg vial with 4mL of water creates the same ratio, proving the calculators flexibility: it applies the same math across different vial sizes and water volumes